Cargando…

DLPFC transcriptome defines two molecular subtypes of schizophrenia

Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowen, Elijah F. W., Burgess, Jack L., Granger, Richard, Kleinman, Joel E., Rhodes, C. Harker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509343/
https://www.ncbi.nlm.nih.gov/pubmed/31073119
http://dx.doi.org/10.1038/s41398-019-0472-z
_version_ 1783417230204076032
author Bowen, Elijah F. W.
Burgess, Jack L.
Granger, Richard
Kleinman, Joel E.
Rhodes, C. Harker
author_facet Bowen, Elijah F. W.
Burgess, Jack L.
Granger, Richard
Kleinman, Joel E.
Rhodes, C. Harker
author_sort Bowen, Elijah F. W.
collection PubMed
description Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophrenics and 206 matched controls. Transcripts from 633 genes are differentially expressed in the DLPFC of schizophrenics as compared to controls at Bonferroni-corrected significance levels. Seventeen of those genes are differentially expressed at very high significance levels (<10(−8) after Bonferroni correction). The findings were closely replicated in a dataset from an entirely unrelated source. The statistical significance of this differential gene expression is being driven by about half of the schizophrenic DLPFC samples, and importantly, it is the same half of the samples that is driving the significance for almost all of the differentially expressed transcripts. Weighted gene co-expression network analysis (WGCNA) of the schizophrenic subjects, based on the transcripts differentially expressed in the schizophrenics as compared to controls, divides them into two groups. “Type 1” schizophrenics have a DLPFC transcriptome similar to that of controls with only four differentially expressed genes identified. “Type 2” schizophrenics have a DLPFC transcriptome dramatically different from that of controls, with 3529 expression array probes to 3092 genes detecting transcripts that are differentially expressed at very high significance levels. These findings were re-tested and replicated in a separate independent cohort, using the RNAseq data from the DLPFC of an independent set of schizophrenics and control subjects. We suggest the hypothesis that these striking differences in DLPFC transcriptomes, identified and replicated in two populations, imply a fundamental biologic difference between these two groups of diagnosed schizophrenics, and we propose specific paths for further testing and expanding the hypothesis.
format Online
Article
Text
id pubmed-6509343
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65093432019-05-16 DLPFC transcriptome defines two molecular subtypes of schizophrenia Bowen, Elijah F. W. Burgess, Jack L. Granger, Richard Kleinman, Joel E. Rhodes, C. Harker Transl Psychiatry Article Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophrenics and 206 matched controls. Transcripts from 633 genes are differentially expressed in the DLPFC of schizophrenics as compared to controls at Bonferroni-corrected significance levels. Seventeen of those genes are differentially expressed at very high significance levels (<10(−8) after Bonferroni correction). The findings were closely replicated in a dataset from an entirely unrelated source. The statistical significance of this differential gene expression is being driven by about half of the schizophrenic DLPFC samples, and importantly, it is the same half of the samples that is driving the significance for almost all of the differentially expressed transcripts. Weighted gene co-expression network analysis (WGCNA) of the schizophrenic subjects, based on the transcripts differentially expressed in the schizophrenics as compared to controls, divides them into two groups. “Type 1” schizophrenics have a DLPFC transcriptome similar to that of controls with only four differentially expressed genes identified. “Type 2” schizophrenics have a DLPFC transcriptome dramatically different from that of controls, with 3529 expression array probes to 3092 genes detecting transcripts that are differentially expressed at very high significance levels. These findings were re-tested and replicated in a separate independent cohort, using the RNAseq data from the DLPFC of an independent set of schizophrenics and control subjects. We suggest the hypothesis that these striking differences in DLPFC transcriptomes, identified and replicated in two populations, imply a fundamental biologic difference between these two groups of diagnosed schizophrenics, and we propose specific paths for further testing and expanding the hypothesis. Nature Publishing Group UK 2019-05-09 /pmc/articles/PMC6509343/ /pubmed/31073119 http://dx.doi.org/10.1038/s41398-019-0472-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bowen, Elijah F. W.
Burgess, Jack L.
Granger, Richard
Kleinman, Joel E.
Rhodes, C. Harker
DLPFC transcriptome defines two molecular subtypes of schizophrenia
title DLPFC transcriptome defines two molecular subtypes of schizophrenia
title_full DLPFC transcriptome defines two molecular subtypes of schizophrenia
title_fullStr DLPFC transcriptome defines two molecular subtypes of schizophrenia
title_full_unstemmed DLPFC transcriptome defines two molecular subtypes of schizophrenia
title_short DLPFC transcriptome defines two molecular subtypes of schizophrenia
title_sort dlpfc transcriptome defines two molecular subtypes of schizophrenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509343/
https://www.ncbi.nlm.nih.gov/pubmed/31073119
http://dx.doi.org/10.1038/s41398-019-0472-z
work_keys_str_mv AT bowenelijahfw dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia
AT burgessjackl dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia
AT grangerrichard dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia
AT kleinmanjoele dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia
AT rhodescharker dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia